WO1997046585A3 - Fragments de leptine (proteine ob) - Google Patents

Fragments de leptine (proteine ob) Download PDF

Info

Publication number
WO1997046585A3
WO1997046585A3 PCT/EP1997/002968 EP9702968W WO9746585A3 WO 1997046585 A3 WO1997046585 A3 WO 1997046585A3 EP 9702968 W EP9702968 W EP 9702968W WO 9746585 A3 WO9746585 A3 WO 9746585A3
Authority
WO
WIPO (PCT)
Prior art keywords
leptin
compound
fragments
protein
analogue
Prior art date
Application number
PCT/EP1997/002968
Other languages
English (en)
Other versions
WO1997046585A2 (fr
Inventor
Kamal A Al-Barazanji
Jonathan Robert Sanders Arch
Patrick Camilleri
William Arthur Neville
Original Assignee
Smithkline Beecham Plc
Al Barazanji Kamal A
Jonathan Robert Sanders Arch
Patrick Camilleri
William Arthur Neville
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9611775.9A external-priority patent/GB9611775D0/en
Priority claimed from GBGB9618540.0A external-priority patent/GB9618540D0/en
Priority claimed from GBGB9703493.8A external-priority patent/GB9703493D0/en
Priority to HU0001774A priority Critical patent/HUP0001774A3/hu
Priority to IL12715397A priority patent/IL127153A0/xx
Priority to AU33372/97A priority patent/AU3337297A/en
Application filed by Smithkline Beecham Plc, Al Barazanji Kamal A, Jonathan Robert Sanders Arch, Patrick Camilleri, William Arthur Neville filed Critical Smithkline Beecham Plc
Priority to JP10500240A priority patent/JP2000512137A/ja
Priority to EP97929156A priority patent/EP0912609A2/fr
Priority to NZ332879A priority patent/NZ332879A/xx
Priority to CA002257240A priority patent/CA2257240A1/fr
Priority to BR9709529A priority patent/BR9709529A/pt
Publication of WO1997046585A2 publication Critical patent/WO1997046585A2/fr
Publication of WO1997046585A3 publication Critical patent/WO1997046585A3/fr
Priority to NO985683A priority patent/NO985683L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

L'invention concerne une leptine, un peptide ob, ou un dérivé fonctionnel, un analogue ou un variant de ceux-ci, modulant le poids corporel essentiellement au moyen d'une modulation de l'utilisation de l'énergie. Elle concerne également une composition pharmaceutique contenant un tel composé, un procédé de préparation de celui-ci, ainsi que l'utilisation de ce composé en médecine.
PCT/EP1997/002968 1996-06-06 1997-06-04 Fragments de leptine (proteine ob) WO1997046585A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BR9709529A BR9709529A (pt) 1996-06-06 1997-06-04 Fragmentos de leptina (proteína ob)
CA002257240A CA2257240A1 (fr) 1996-06-06 1997-06-04 Fragments de leptine (proteine ob)
NZ332879A NZ332879A (en) 1996-06-06 1997-06-04 Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes
IL12715397A IL127153A0 (en) 1996-06-06 1997-06-04 Fragments of leptin (ob protein)
AU33372/97A AU3337297A (en) 1996-06-06 1997-06-04 Fragments of leptin (ob protein)
HU0001774A HUP0001774A3 (en) 1997-02-20 1997-06-04 Fragments of leptin (ob protein)
JP10500240A JP2000512137A (ja) 1996-06-06 1997-06-04 レプチン（ｏｂタンパク質）のフラグメント
EP97929156A EP0912609A2 (fr) 1996-06-06 1997-06-04 Fragments de leptine (proteine ob)
NO985683A NO985683L (no) 1996-06-06 1998-12-04 Fragmenter av leptin (ob protein)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9611775.9A GB9611775D0 (en) 1996-06-06 1996-06-06 Novel compounds
GB9611775.9 1996-06-06
GBGB9618540.0A GB9618540D0 (en) 1996-09-05 1996-09-05 Novel compounds
GB9618540.0 1996-09-05
GBGB9703493.8A GB9703493D0 (en) 1997-02-20 1997-02-20 Novel compounds
GB9703493.8 1997-02-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09194866 A-371-Of-International 1998-12-04
US09/844,774 Continuation US20020037553A1 (en) 1996-06-06 2001-04-27 Fragments of leptin (ob protein)

Publications (2)

Publication Number Publication Date
WO1997046585A2 WO1997046585A2 (fr) 1997-12-11
WO1997046585A3 true WO1997046585A3 (fr) 1998-04-23

Family

ID=27268305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/002968 WO1997046585A2 (fr) 1996-06-06 1997-06-04 Fragments de leptine (proteine ob)

Country Status (15)

Country Link
EP (1) EP0912609A2 (fr)
JP (1) JP2000512137A (fr)
KR (1) KR20000016402A (fr)
CN (1) CN1221426A (fr)
AR (1) AR008765A1 (fr)
AU (1) AU3337297A (fr)
BR (1) BR9709529A (fr)
CA (1) CA2257240A1 (fr)
CZ (1) CZ397898A3 (fr)
IL (1) IL127153A0 (fr)
NO (1) NO985683L (fr)
NZ (1) NZ332879A (fr)
PL (1) PL330361A1 (fr)
TR (1) TR199802534T2 (fr)
WO (1) WO1997046585A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756617B2 (en) 1998-07-28 2003-01-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) * 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU782230B2 (en) * 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
AU8178401A (en) 2000-05-22 2001-12-03 Vlaams Interuniv Inst Biotech Receptor-based interaction trap
PL214862B1 (pl) 2001-10-22 2013-09-30 Amgen Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
ATE390144T1 (de) 2003-09-08 2008-04-15 Serono Lab Behandlung von fibrosen
WO2005077072A2 (fr) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Polypeptides hybrides presentant des proprietes pouvant etre choisies
EP1812038A1 (fr) 2004-11-18 2007-08-01 VIB vzw Domaine de fibronectine iii servant d'antagonistes de recepteurs de la leptine
WO2007022123A2 (fr) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Polypeptides hybrides presentant des proprietes selectionnables
EP2390264A1 (fr) 2005-02-11 2011-11-30 Amylin Pharmaceuticals Inc. Analogues de GIP et polypeptides hybrides de GIP aux propriétés sélectionnables
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
ES2319048B1 (es) * 2007-06-20 2010-02-10 Universitat De Les Illes Balears Uso de leptina en el tratamiento de alteraciones en los habitos alimentarios.
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
GB2451858A (en) * 2007-08-15 2009-02-18 Sergiy Konovchuk Methods of reducing body fat and treating obesity
AU2008333173A1 (en) 2007-12-05 2009-06-11 Astrazeneca Ab Piperazines as anti-obesity agents
CN102015668A (zh) 2007-12-05 2011-04-13 阿斯利康(瑞典)有限公司 用作瘦蛋白受体调节剂的哌嗪衍生物及其用途
KR20110015446A (ko) * 2008-06-04 2011-02-15 아스트라제네카 아베 렙틴 수용체 조절제 유사체로서의 신규한 피리딘 유도체
MX2010013355A (es) * 2008-06-04 2010-12-21 Astrazeneca Ab Nuevos compuestos v.
JP2012523434A (ja) 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ，インコーポレイテッド エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
ES2602436T3 (es) * 2010-05-11 2017-02-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Inhibidor basado en péptido de la activación de interleucina 10 o STAT-3
ES2641869T3 (es) 2010-09-28 2017-11-14 Aegerion Pharmaceuticals, Inc. Polipéptidos de fusión de leptina-ABD con duración de acción aumentada
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005309A2 (fr) * 1994-08-17 1996-02-22 The Rockefeller University Modulateurs de masse corporelle, proteines et acides nucleiques correspondants, et utilisations a des fins therapeutiques et diagnostiques
WO1996023815A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Anticorps contre les produits du gene ob
WO1996023519A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines agissant contre l'obesite
WO1996023514A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines anti-obesite
WO1996031526A1 (fr) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Agents antiobesite
WO1996034885A2 (fr) * 1995-05-05 1996-11-07 Smithkline Beecham Plc Fragments peptidiques biologiquement actifs de proteines ob

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005309A2 (fr) * 1994-08-17 1996-02-22 The Rockefeller University Modulateurs de masse corporelle, proteines et acides nucleiques correspondants, et utilisations a des fins therapeutiques et diagnostiques
WO1996023815A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Anticorps contre les produits du gene ob
WO1996023519A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines agissant contre l'obesite
WO1996023514A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines anti-obesite
WO1996031526A1 (fr) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Agents antiobesite
WO1996034885A2 (fr) * 1995-05-05 1996-11-07 Smithkline Beecham Plc Fragments peptidiques biologiquement actifs de proteines ob

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE TOXLIT AN 1970:3841 *
K.C. SAXENA ET AL.: "Hydrolysis of Peptides containing D-amino acids by Rabbit Tissues", INDIAN JOURNAL OF BIOCHEMISTRY, vol. 6, no. 4, 1969, pages 226 - 227 *

Also Published As

Publication number Publication date
PL330361A1 (en) 1999-05-10
AR008765A1 (es) 2000-02-23
CZ397898A3 (cs) 1999-04-14
NO985683D0 (no) 1998-12-04
AU3337297A (en) 1998-01-05
CA2257240A1 (fr) 1997-12-11
JP2000512137A (ja) 2000-09-19
CN1221426A (zh) 1999-06-30
EP0912609A2 (fr) 1999-05-06
BR9709529A (pt) 1999-08-10
TR199802534T2 (xx) 1999-03-22
WO1997046585A2 (fr) 1997-12-11
NZ332879A (en) 2000-09-29
KR20000016402A (ko) 2000-03-25
IL127153A0 (en) 1999-09-22
NO985683L (no) 1998-12-04

Similar Documents

Publication Publication Date Title
WO1997046585A3 (fr) Fragments de leptine (proteine ob)
AU4867697A (en) Oxadiazoles, processes for preparing them and their use as pharmaceutical compositions
WO1998007745A3 (fr) Compositions et methodes pour traitement des infections, utilisant des analogues d'indolicidine
HK1017257A1 (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants.
AU4397297A (en) Antibody against human parathormone related peptides
EP1077217A3 (fr) Peptides neuroactives et leur utilisation
AU4552097A (en) 7alpha-(epsilon-aminoalkyl)estratrienes, process for preparing the same, pharmaceutical preparations containing said 7alpha-(epsilo-aminoalkyl)estratrienes and their use for preparing medicaments
AU6373094A (en) Enzyme-containing pharmaceutical or cosmetic composition, process for preparing the same and its use
WO1996040757A3 (fr) Peptides antagonistes de la lh-rh
IL106600A0 (en) Peptides,pharmaceutical compositions containing the same and processes for the preparation thereof
AU1607497A (en) Novel aromatic piperazines derived from substituted cycloazanes, method for preparing same, pharmaceutical compositions, and use thereof as drugs
WO1999032135A8 (fr) Formulations du facteur-2 de croissance des keratinocytes
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
AU2974189A (en) Pharmaceutical compositions containing lactams, new substituted lactams and processes for the preparation thereof
AU3868997A (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
AU683787B2 (en) Aromatic heterocyclic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
EP0998942A4 (fr) Procede de stabilisation de peptides et compositions medicinales lyophilisees comprenant des peptides obtenus par ce procede
AU5812800A (en) Pharmaceutical preparation
EP0783521B8 (fr) Composes polypeptides contenant d-2-alkyltryptophanne pouvant promouvoir la liberation de l'hormone de croissance
AU4515497A (en) 3-amidochromanylsulfony(thio)ureas, processes for their preparation, their use, and pharmaceutical preparations comprising them
AU1638095A (en) Boronic peptide derivatives, preparation and therapeutic application thereof
AU6858594A (en) Human influenza virus peptides binding hla-t molecule
EP1304118A3 (fr) Emplois thérapeutiques des produits de la protéine BPI
IL110954A0 (en) Pharmaceutical compositions comprising a retinoblastoma polypeptide or protein, and methods for the preparation and use thereof
EP0770875A3 (fr) Marqueur et réactif pour diabète sucré et complication du diabète sucré

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97195311.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 332879

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV1998-3978

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2257240

Country of ref document: CA

Ref document number: 2257240

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998/02534

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/010406

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1997929156

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-3978

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1997929156

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997929156

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-3978

Country of ref document: CZ